Abstract
Background
Administration of interleukin-2 (IL-2) is limited by the induction of the vascular leak syndrome (VLS).
Aims
To examine the effect of taurine on the toxicity and antitumour activity of IL-2 in a B16 melanoma pulmonary metastases model.
Methods
B16 melanoma cells were injected into female C57BL/6 mice. Macroscopic melanoma pulmonary foci were established by day 10 in untreated mice. Treated mice were randomised into treatment by rIL-2 alone, rlL-2 plus taurine or taurine alone. Control animals received saline. Mice were sacrificed on day 18. Lung metastases were counted in a blinded fashion with the aid of a dissecting microscope. Wet to dry lung weight was measured following lung removal. In another experiment animals were treated as above (n=15 per group) and survival following treatment monitored.
Result
Treatment with IL-2 and taurine significantly reduced lung nodules compared with IL-2 alone. Host survival was significantly enhanced. The wet to dry (w/d) ratios of lung weights in the group receiving IL-2/taurine were significantly less than IL-2 alone. Bronchoalveolar lavage protein fluid was reduced indicating reduced pulmonary injury.
Conclusion
These findings indicate that the combination of taurine with IL-2 augments the efficacy of this immunotherapy while reducing its associated dose-limiting toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rosenberg SA, Mule JJ, Speiss RJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumour mediated by the systemic administration of high-dose recombinant interleukin-2.J Rxp Med 1985; 161: 1169–88.
Rosenberg SA, Lotze MT, Muul LM. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone.N Engl J Med 1987; 316: 889–97.
Ettinghausen SE, Rosenberg SA. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant IL-2.Cancer Res 1986: 46; 2784–92.
Schuchter LM, Esa AH, May WS et al. Successful treatment of murine melanoma with bryostatinl.Cancer Res 1991; 51: 682–87.
Whitehead RP, Friedman KD, Clark DA, Pagani K, Rapp L. Phase I trial of simultaneous administration of interleukin 2 and interleukin-4 subcutaneously.Clin Cancer Res 1995; 1: 1145–52.
Mier JW. Abrogation of interleukin-2 toxicity. In: Therapeutic applications of Interleukin-2. New York: Marcel Dekker Inc., 1995: p 455–475.
Nishio S-I, Negoro S, Hosokawa T et al. The effect of taurine on age-related immune decline in mice: the effect of taurine on T cell and B cell proliferative response under costimulation with ionomycin and phorbol myristate acetate. In: Mechanisms of Aging and Development. Ireland Elsevier Scientific Publishers Ltd. 1990: p 125–139.
Huxtable, R. Physiological actions of taurine.Physiol Rev 1992; 72: 101–63.
Wang JH, Redmond HP, Watson RWG, Condron CC, Bouchier-Hayes D. The beneficial effects of taurine on the prevention of human endothelial cell death.Shock 1996; 6: 331–38.
Watson RWG, Redmond HP, Bouchier-Hayes D. Taurine up-regulates antimicrobial function of human inflammatory cells through a calcium-dependent mechanism.Surg Forum 1994; 80: 573–75.
Damle NK, Doyle LV, Bender JR, Bradley EC. Interleukin-2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis.J Immunol 1987; 138: 1779–85.
Kitayama J, Tsuno N, Yasuhara H, et al. Lysis of endothelial cells by autologous lymphokine-activated killer cells.J Immunol 1994; 38: 317–22.
Fujita S, Puri RK, Yu Z-X, Travis WD, Ferrans VJ. An ultrastructural study of in-vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2.Cancer 1991; 68: 2169–74.
Richards AL, Djeu JY. Calcium-dependent natural killer and calcium-independent natural cytotoxic activities in an IL-2-dependent killer cell line.J Immunol 1990; 145: 3144–49.
Ryan JC, Niemi EC, Goldfien RD, Hiserodt JC, Seaman WE. NKR-P1, an activating molecule on rat natural killer cells, stimulates phosphoinositide turnover and a rise in intracellular calcium.J Immunol 1991; 147: 3244–50.
Kotasek D, Vercellotti GM, Ochoa AC et al. Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells.Cancer Res 1988; 48: 5528–32.
Finnegan N, Redmond HP, Bouchier-Hayes D. Taurine attenuates recombinant IL-2 activated, lymphocyte mediated endothelial cell injury.Cancer Res 1998; 82: 186–99.
Rinehart JJ, Triozzi PL, Lee MH, Aldrich W, Young D. Modulation of hematologic and immunologic effects of high dose chemotherapy by IL-2 in a murine tumour model.Mol Biotber 1992; 4: 77–82.
Lode HN, Xiang R, Varki NM et al. Targeted IL-2 therapy for spontaneous neuroblastoma metastases to bone marrow.J Natl Cancer Inst 1997; 89: 1586–94.
Cheever MA, Thompson JA, Kern DE, Greenberg PD. Interleukin 2 (IL 2) administered in vivo: influence of IL-2 route and timing on T cell growth.J Immunol 1985; 134: 3895–900.
Da Costa ML, Redmond HP, Bouchier-Hayes D. The effect of laparotomy and laparoscopy on the establishment of spontaneous tumour metastases.Surgery 1998; 124: 516–21.
Da Costa, ML, Redmond HP, Bouchier-Hayes D. Taurolidene improves survival by abrogating the accelerated development and proliferation of solid tumours and development of organ metastases from circulating tumour cells released following surgery.J Surg Res 2001; 101: 1–9.
Peto R, Pike MC, Armitage P et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples.Br J Cancer 1977; 35: 1–39.
Mastino A, Favalli C, Greili S, Innocenti F, Garaci E. Thymosin potentiates interleukin 2-induced cytotoxic activity in mice.Cellular Immunol 1991; 133: 196–205.
Sznol M, Thurn A, Aronson FR. Interleukin-2 in combination with other biologic agents. In: Therapeutic applications of Interleukin-2, New York, Marcel Dekker Inc. 1993: p 233–75.
Silva MA, Cunha GM, Viana GS, Rao VS. Taurine modulates chemical nociception in mice.Braz J Med Biol Res 1993; 26: 1319–24.
Nakajima I, Ozaki M, Jinnai H et al. Enhanced activity against syngeneic murine tumours by intrasplenic injection of recombinant interleukin-2 (IL-2) and interleukin-1 (IL-1).Cancer Biotherapy 1993; 8: 319–26.
Puri RK, Leland P. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.Clin Exp Immunol 1991; 85: 317–25.
Finnegan N. The role of taurine in vitro. In: The role of taurine in IL-2 immunotherapy. PhD Thesis, TCD Dublin. 1998; 71–88.
Milei J, Ferreira R, Llesuy S et al. Reduction of reperfusion injury with preoperative rapid intravenous infusion of taurine during myocardial revascularisation.Am Heart J 1992; 123: 339–45.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Finnegan, N., Toomey, D., Condron, C. et al. Potentiation of the therapeutic index of interleukin-2 immunotherapy by combination with taurine in a syngeneic murine tumour model. Ir J Med Sci 171, 85–88 (2002). https://doi.org/10.1007/BF03168959
Issue Date:
DOI: https://doi.org/10.1007/BF03168959